Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.

Abstract

LBA1 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Sunday, June 4, 2017, and in the Annual Meeting Proceedings online supplement to the June 20, 2017, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

S3-Leitlinie – Kolorektales Karzinom

“…der IDEA ("International Duration Evaluation of Adjuvant Therapy") vorgestellt [925]. Diese Studie war darauf ausgelegt, die Nichtunterlegenheit einer 3-monatigen vs. 6 Vor dem Hintergrund dieser Gegebenheiten und der Tatsache, dass die Daten noch nicht publiziert sind, wurden diese Studienergebnisse noch nicht als Basis für eine ergänzende Leitlinienempfehlung herangezogen.…”

How much is enough: 3 versus 6 months of adjuvant therapy for colon cancer

“…To clearly demonstrate that there was no loss of effectiveness, six large randomized clinical trials done globally were prospectively planned to be analyzed together to answer the question of the noninferiority of 3 months of oxaliplatin-based chemotherapy compared with 6 months [1]. This study was presented initially at the 2017 ASCO meeting [6] and, in my opinion, represents a landmark moment for us and for our patients.…”

Lymph node retrieval using fat dissolution technique after surgical resection of colorectal cancer: a protocol paper

“…It is necessary to examine an appropriate number of lymph nodes for accurate diagnosis of node negativity. In addition, being able to discriminate between N1 and N2 status could be an important factor in determining the length of adjuvant chemotherapy in Stage III colon cancer 6) . In this regard, the fat-dissolution method may contribute to treatment decisions regarding Stage II and III colon cancer.…”